Search

Displaying results 5451 - 5460 of 10000 in total
  1. Drug

    Penequinine, Penehyclidine

    go.drugbank.com/drugs/DB16287
    Investigational

    Penequinine, Penehyclidine is under investigation in clinical trial NCT02644876 (Preventive Effects of Penehyclidine Hydrochloride Inhalation on Postoperative Pulmonary Complications).

  2. Drug

    Phosphonoacetic Acid

    go.drugbank.com/drugs/DB02823
    Experimental

    A simple organophosphorus compound that inhibits DNA polymerase, especially in viruses and is used as an antiviral agent. [PubChem]

  3. Drug

    Garden snail mucin

    go.drugbank.com/drugs/DB14244
    Investigational

    Garden snail mucin is an animal extract used in some OTC (over-the-counter) products. It is not an approved drug.

  4. Drug

    Menaquinone 7

    go.drugbank.com/drugs/DB13075
    Investigational

    Menaquinone 7 is under investigation in clinical trial NCT00402974 (The Effect of Vitamin K Supplementation on Osteocalcin Carboxylation in Healthy Children).

  5. Drug

    Onvitrelin ucalontide

    go.drugbank.com/drugs/DB19183
    Investigational

    Onvitrelin ucalontide is under investigation in clinical trial NCT01485848 (EP-100 Plus Paclitaxel Versus Paclitaxel Alone in Patients With Ovarian Cancer).

    Synonyms: Ep-100 (conjugate of luteinizing hormone-releasing hormone with a cationic .alpha.-helical peptide for therapy of lhrh-expressing tumors), Ep-100 (peptide)
  6. Drug

    Cediranib

    go.drugbank.com/drugs/DB04849
    Investigational

    The novel indole-ether quinazoline Cediranib is a highly potent (IC<sub>50</sub> &lt; 1 nmol/L) ATP-competitive inhibitor of recombinant KDR tyrosine kinase in vitro. … It is being developed clinically as a once-daily oral therapy for the treatment of cancer.

  7. Drug

    Indisulam

    go.drugbank.com/drugs/DB06370
    Investigational

  8. Drug

    SYNB1020

    go.drugbank.com/drugs/DB17667
    Investigational

    discontinued further development of SYNB1020 to treat hyperammonemia due to a lack of evidence of ammonia-lowering activities by SYNB1020 in a Phase 1b/2a study. … It was initially designed to convert ammonia to L-arginine [A258838] and granted orphan designation by the FDA for the treatment of urea cycle disorders in August 2016;[L45988] however, the manufacturer

  9. Drug

    R112

    go.drugbank.com/drugs/DB06252
    Experimental

    R112 is an investigational compound developed to treat Allergic Rhinitis. It's mechanism of action is to inhibit SYK kinase.

  10. Drug

    LY-2623091

    go.drugbank.com/drugs/DB15367
    Investigational

    LY-2623091 is under investigation in clinical trial NCT02194465 (A Study of LY2623091 in Participants With High Blood Pressure).